Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug

• Pacira BioSciences Inc (NASDAQ: PCRX) announced topline results from its Phase 3 study of EXPAREL as a single-dose femoral nerve block in the adductor canal for postsurgical regional analgesia in patients undergoing total knee arthroplasty.

• EXPAREL achieved the study's primary endpoint demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl.

• EXPAREL also achieved a statistically significant reduction in postsurgical opioid consumption through 96 hours compared with bupivacaine HCl.

• EXPAREL was well tolerated with a safety profile consistent with bupivacaine HCl.

• Pacira plans to submit a supplemental marketing application to the FDA early next year seeking expansion of the EXPAREL label to include femoral nerve block in the adductor canal.

• The company plans to submit the full results from the Phase 3 study for presentation at future scientific conferences and publication in a peer-reviewed journal.

• Price Action: PCRX shares are up 0.35% at $51.42 on the last check Wednesday.

See more from Benzinga

• Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs

• Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate

• Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.